4 quarters tracked · Beat rate 50% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $4.66 | $6.34 | +36.1% | Beat |
| Q4 2025 | 2025-12-31 | $6.65 | $6.64 | -0.1% | Miss |
| Q3 2025 | 2025-09-30 | $6.04 | $8.13 | +34.7% | Beat |
| Q2 2025 | 2025-06-30 | $-7.76 | $-8.25 | -6.4% | Miss |
Earnings Beat Rate
Jazz Pharmaceuticals has beaten analyst EPS estimates in 2 of 4 tracked quarters (50% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →